Identifying Molecular Drivers of Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02470715 |
Recruitment Status :
Completed
First Posted : June 12, 2015
Last Update Posted : May 25, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cancer Tumor Advanced Cancer | Genetic: Molecular profile |
Study Type : | Observational |
Actual Enrollment : | 579 participants |
Observational Model: | Other |
Time Perspective: | Other |
Official Title: | Identifying Molecular Drivers of Cancer |
Actual Study Start Date : | April 2014 |
Actual Primary Completion Date : | May 22, 2018 |
Actual Study Completion Date : | May 22, 2018 |
Group/Cohort | Intervention/treatment |
---|---|
Molecular profile
Molecular profiled group receiving treatment based on genetics
|
Genetic: Molecular profile
Patients and their treating physician will obtain the patient's genetic risk assessment
Other Name: Genomic targeting |
- Genetic profiling [ Time Frame: Up to 15 years ]To determine genetic changes associated with the development and growth of human disease. This should lead to better ways to detect, prevent, and treat a wide variety of human health conditions, including cancer.
Biospecimen Retention: Samples With DNA
Participants will have up to 3 blood tubes (about 30 ml) drawn under the condition that protocol criteria for blood sampling is met. Blood samples may be collected each time a participant undergoes a provider-ordered blood draw. Urine samples may also be collected approximately every 4-6 weeks.
Participants may be asked to provide approximately 60-120 ml of first-morning-void urine. Tissue from a standard care surgical procedure or biopsy may be obtained. Additional core biopsies (for research) or excess surgical waste will be collected during each biopsy procedure when appropriate and will be processed and stored.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Patients diagnoses with cancer but healthy enough to undergo a biopsy procedure
- Between the ages of 18 and 100
Exclusion Criteria:
- Patients who are pregnant

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02470715
United States, South Dakota | |
Avera Cancer Institute | |
Sioux Falls, South Dakota, United States, 57105 |
Principal Investigator: | Brian Leyland-Jones | Avera McKennan Hospital & University Health Center |
Responsible Party: | Avera McKennan Hospital & University Health Center |
ClinicalTrials.gov Identifier: | NCT02470715 |
Other Study ID Numbers: |
AMEM-2014-CCD001 |
First Posted: | June 12, 2015 Key Record Dates |
Last Update Posted: | May 25, 2018 |
Last Verified: | May 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
genetic sequencing genome cancer DNA |
RNA protein metabolite |